PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
Status:
Completed
Trial end date:
2018-02-21
Target enrollment:
Participant gender:
Summary
This is a pharmacodynamic study to evaluate the effect of gefitinib as induction therapy for
patients who have resectable, Epidermal growth factor receptor (EGFR) sensitizing mutation
lung cancer.